These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 12574949

  • 1. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.
    Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F.
    J Neurol; 2003 Feb; 250(2):188-93. PubMed ID: 12574949
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
    Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L.
    Pain; 2009 Jan; 141(1-2):60-9. PubMed ID: 19004549
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin.
    Schulte-Mattler WJ, Opatz O, Blersch W, May A, Bigalke H, Wohlfahrt K.
    J Neurol Sci; 2007 Sep 15; 260(1-2):38-42. PubMed ID: 17481662
    [Abstract] [Full Text] [Related]

  • 4. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model.
    Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, Auff E.
    Anesth Analg; 2006 Feb 15; 102(2):509-16. PubMed ID: 16428552
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin.
    Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P.
    Pain; 2007 Jul 15; 130(1-2):76-83. PubMed ID: 17194546
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin.
    Gazerani P, Pedersen NS, Drewes AM, Arendt-Nielsen L.
    Br J Dermatol; 2009 Oct 15; 161(4):737-45. PubMed ID: 19624547
    [Abstract] [Full Text] [Related]

  • 7. Differential effect of Incobotulinumtoxin A on pain, neurogenic flare and hyperalgesia in human surrogate models of neurogenic pain.
    Diener SA, Breimhorst M, Vogt T, Krämer HH, Drummond PD, Geber C, Birklein F.
    Eur J Pain; 2017 Sep 15; 21(8):1326-1335. PubMed ID: 28440002
    [Abstract] [Full Text] [Related]

  • 8. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
    Favre-Guilmard C, Auguet M, Chabrier PE.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):48-53. PubMed ID: 19576881
    [Abstract] [Full Text] [Related]

  • 9. Psychophysics, flare, and neurosecretory function in human pain models: capsaicin versus electrically evoked pain.
    Geber C, Fondel R, Krämer HH, Rolke R, Treede RD, Sommer C, Birklein F.
    J Pain; 2007 Jun 01; 8(6):503-14. PubMed ID: 17434803
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
    Schlereth T, Mouka I, Eisenbarth G, Winterholler M, Birklein F.
    Auton Neurosci; 2005 Feb 07; 117(2):120-6. PubMed ID: 15664565
    [Abstract] [Full Text] [Related]

  • 11. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.
    Birklein F, Walther D, Bigalke H, Winterholler M, Erbguth F.
    Ann Neurol; 2002 Jul 07; 52(1):68-73. PubMed ID: 12112049
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation.
    Krämer HH, Schmidt K, Leis S, Schmelz M, Sommer C, Birklein F.
    Exp Neurol; 2005 Sep 07; 195(1):179-84. PubMed ID: 15963503
    [Abstract] [Full Text] [Related]

  • 13. Diphenyl diselenide attenuates acute thermal hyperalgesia and persistent inflammatory and neuropathic pain behavior in mice.
    Savegnago L, Jesse CR, Pinto LG, Rocha JB, Nogueira CW.
    Brain Res; 2007 Oct 17; 1175():54-9. PubMed ID: 17888416
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia.
    Serra J, Campero M, Bostock H, Ochoa J.
    J Neurophysiol; 2004 Jun 17; 91(6):2770-81. PubMed ID: 14762154
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of adrenosensitivity in capsaicin induced hyperalgesia.
    Schattschneider J, Zum Buttel I, Binder A, Wasner G, Hedderich J, Baron R.
    Eur J Pain; 2007 Oct 17; 11(7):756-63. PubMed ID: 17234439
    [Abstract] [Full Text] [Related]

  • 17. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain.
    Luvisetto S, Marinelli S, Cobianchi S, Pavone F.
    Neuroscience; 2007 Mar 02; 145(1):1-4. PubMed ID: 17218063
    [Abstract] [Full Text] [Related]

  • 18. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization.
    Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L.
    Pain; 2006 Jun 02; 122(3):315-325. PubMed ID: 16677761
    [Abstract] [Full Text] [Related]

  • 19. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction.
    Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kamioka H, Yamashiro T, Kuboki T, Oguma K.
    Neuroscience; 2009 Apr 10; 159(4):1422-9. PubMed ID: 19409226
    [Abstract] [Full Text] [Related]

  • 20. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain.
    Bach-Rojecky L, Lacković Z.
    Croat Med J; 2005 Apr 10; 46(2):201-8. PubMed ID: 15849840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.